Yahoo · Sep 3, 2026
State Street Real Return ETF (RLY) Touches New 52-Week High
State Street Multi-Asset Real Return ETF hits a 52-week high as inflation concerns, easing policy expectations and real assets support gains.
RL
AMEX · RLY
SPDR SSgA Multi-Asset Real Return ETF
Financial Services · Asset Management
$37.69
Up+$0.31 (+0.83%)
Updated Sep 16, 2026, 7:14 AM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 645.9M
- P/E ratio
- —
- Dividend yield
- 2.09%
- 52-week range
- $34.23 – $38.38
- Volume
- 221.22K
- Avg. volume
- 68.6K
Price performance
RLY price history
1M range · 20 trading sessions · Daily adjusted prices
RLY closed at $37.69 after 20 trading sessions, up 1.92% for the selected period.
- Last close
- $37.69
- Period change
- +1.92%
- Period low
- $36.98
- Period high
- $38.16
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $37.57 | $37.715 | $37.48 | $37.69 | 221.22K |
| Sep 14, 2026 | $37.59 | $37.66 | $37.38 | $37.38 | 125.31K |
| Sep 11, 2026 | $37.89 | $37.959 | $37.7061 | $37.77 | 155.19K |
| Sep 10, 2026 | $38.20 | $38.20 | $37.8501 | $37.90 | 446.24K |
| Sep 9, 2026 | $38.23 | $38.38 | $38.0514 | $38.16 | 87.83K |
| Sep 8, 2026 | $37.84 | $38.21 | $37.84 | $38.08 | 133.58K |
| Sep 4, 2026 | $37.63 | $37.8893 | $37.61 | $37.85 | 329.85K |
| Sep 3, 2026 | $38.14 | $38.27 | $37.85 | $37.94 | 138.29K |
| Sep 2, 2026 | $37.85 | $37.89 | $37.6565 | $37.89 | 503.79K |
| Sep 1, 2026 | $37.61 | $37.729 | $37.51 | $37.71 | 318.54K |
| Aug 31, 2026 | $37.42 | $37.65 | $37.42 | $37.60 | 156.83K |
| Aug 28, 2026 | $37.82 | $37.82 | $37.36 | $37.45 | 133.12K |
| Aug 27, 2026 | $37.71 | $37.74 | $37.4214 | $37.67 | 110.49K |
| Aug 26, 2026 | $37.71 | $37.76 | $37.585 | $37.68 | 104.05K |
| Aug 25, 2026 | $37.75 | $37.76 | $37.42 | $37.72 | 331.42K |
| Aug 24, 2026 | $37.79 | $37.84 | $37.605 | $37.72 | 410.36K |
| Aug 21, 2026 | $37.81 | $37.8899 | $37.7511 | $37.83 | 115.04K |
| Aug 20, 2026 | $37.46 | $37.65 | $37.4505 | $37.56 | 356.01K |
| Aug 19, 2026 | $37.34 | $37.50 | $37.19 | $37.41 | 141.1K |
| Aug 18, 2026 | $37.06 | $37.11 | $36.94 | $36.98 | 113.87K |
Latest RLY news
The latest Smart Investors Daily articles mentioning RLY.
Stock researchCompany · Overview
RLY research
Overview
Company profile and research snapshot.
Company profile
Under normal circumstances, the Adviser invests at least 80% of the net assets of the fund among ETPs that provide exposure to the following primary asset classes: (i) inflation protected securities issued by the United States government; (ii) domestic and international real estate securities; (iii) commodities; (iv) publicly-traded domestic and international infrastructure companies; and (iv) publicly-traded companies in natural resources and/or commodities businesses.
Analyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
globenewswire.com · Dec 12, 2025
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025
Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer, regardless of prior fulvestrant or other SERD exposure, or ESR1 mutation status Phase 3 ReDiscover-2 trial in CDK4/6-experienced breast cancer ongoing CAMBRIDGE, Mass., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced a subset analysis of interim clinical data for zovegalisib (RLY-2608), the first known investigational allosteric, pan-mutant and isoform-selective inhibitor of PI3Kα.
defenseworld.net · Nov 30, 2025
SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY) Reaches New 52-Week High – Should You Buy?
SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY - Get Free Report) hit a new 52-week high during trading on Friday. The company traded as high as $31.76 and last traded at $31.7240, with a volume of 4621 shares trading hands. The stock had previously closed at $31.56. SPDR SSgA Multi-Asset Real Return ETF Trading
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
